Related Experiment Video

Updated: Oct 25, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.4K

Triple-negative breast cancer: understanding Wnt signaling in drug resistance

Parnaz Merikhian1, Mohammad Reza Eisavand1, Leila Farahmand2

  • 1Recombinant protein department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, 146, South Gandhi Ave., Vanak Circus, Tehran, Iran.

Cancer Cell International
|August 11, 2021
PubMed

Insights

Triple-negative breast cancer (TNBC) exhibits resistance to therapies due to Wnt/β-catenin signaling. Understanding its interaction with other pathways is key to developing effective combination treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) is a heterogeneous cancer subtype lacking targeted therapies.
  • TNBC is associated with poor patient survival and resistance to existing treatments.
  • Wnt/β-catenin signaling is frequently deregulated in TNBC, contributing to therapeutic resistance.

Purpose of the Study:

  • To review the mechanisms of Wnt/β-catenin signaling in TNBC resistance.
  • To explore the interactions between Wnt/β-catenin signaling and other cancer-promoting pathways.
  • To inform the development of novel combination therapies for TNBC.

Main Methods:

  • Literature review of studies on Wnt/β-catenin signaling in TNBC.
  • Analysis of molecular and clinical data related to TNBC progression.
  • Examination of pathway crosstalk in cancer development and resistance.

Main Results:

  • Wnt/β-catenin signaling promotes TNBC resistance through various mechanisms.
  • Interactions with receptor tyrosine kinase (RTK) pathways, EMT, and metastasis are critical.
  • Lymphocytic infiltration is influenced by Wnt/β-catenin signaling in TNBC.

Conclusions:

  • Targeting Wnt/β-catenin signaling offers potential for overcoming TNBC resistance.
  • Combination therapies involving Wnt/β-catenin modulators may improve outcomes.
  • Further research into pathway interactions is crucial for effective TNBC treatment strategies.
Keywords:
Combination therapyDrug resistanceTriple negative breast cancers (TNBCs)TumorigenesisWnt/β-catenin

More Related Videos

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

4.7K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.8K

Related Concept Videos

Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.7K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K